Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2003
08/28/2003US20030162752 Sulphamate compounds for inhibiting oestrone sulphatase activity and aromatase activity; anticarcinogenic agents
08/28/2003US20030162751 Pharmaceutical composition comprising 5' monophosphate ester of riboflavin and solubilized riboflavin
08/28/2003US20030162749 Use of cdp-choline for the treatment of alcohol withdrawal syndrome
08/28/2003US20030162748 Comprises liposomes attached to prodrugs through phosphonate linkages; phospholipases; targets liver/spleen
08/28/2003US20030162747 Administering otoprotectant glutathione peroxidase mimic (ebselen), xanthine oxidase inhibitor (allopurinol), and glutathione precursor (N-acetylcysteine)
08/28/2003US20030162744 Salmon-origin chondroitin sulfate
08/28/2003US20030162743 Matrix metalloproteinase and tumor necrosis factor inhibitors
08/28/2003US20030162742 Oral administration of methyl-4-(3-(9-6-aminopurin-2-yl)) prop-2-ynyl)cyclohexane-carboxylate, having A2A adenosine receptor antagonist activity
08/28/2003US20030162740 Strategy for leukemia therapy
08/28/2003US20030162737 Preventives and remedies for pulmonary hypertension
08/28/2003US20030162736 Medicament comprising NK4 gene or recombinant NK4 protein
08/28/2003US20030162734 Inhibiting interaction of antisense nucleotides with jun-N-terminal kinases (JNKs) via administering 4-(4-fluoro-phenyl)-2-(4-methlysulfinylphenyl)-5-(4-pyridyl)-1H-imidazole; stem cells
08/28/2003US20030162732 Combination of aminosugars and cysteine or cysteine derivatives
08/28/2003US20030162730 Crystal forms of azithromycin
08/28/2003US20030162727 Use of cyp1b1inhibitors for treating cancer
08/28/2003US20030162726 Sugar-free products with improved characteristics
08/28/2003US20030162725 Comprises 5-hydroxytryptophan (for enhancing serotonin-mediated neurotransmission), vitamin B6, epigallocatechin gallate (EGCG, for enhancing thermogenesis), caffeine, and anorectic agents
08/28/2003US20030162723 Supplementation of equine feedstuffs
08/28/2003US20030162722 Pharmaceutical compositions comprising acryloyl distamycin derivatives and topoisomerase I and II inhibitors
08/28/2003US20030162719 Immobilization of active materials
08/28/2003US20030162716 Methods useful in the treatment of bone resorption diseases
08/28/2003US20030162695 Glucocorticoid blocking agents for increasing blood-brain barrier permeability
08/28/2003US20030162694 Novel treatment for pathological aggression
08/28/2003US20030162691 Novel antimicrobial therapies
08/28/2003US20030162690 Bood anticoagulant
08/28/2003US20030162300 Galactomannan-oligosaccharides and methods for the production and use thereof
08/28/2003US20030162206 Central nervous system disorders; antiinflammatory agnets; antidiabetic agents
08/28/2003US20030162194 Diagnosis of diseases associated with apoptosis
08/28/2003US20030162175 NK cell receptor polynucleotides, polypeptides, and antibodies
08/28/2003US20030161957 Impregnating polymer with active ingredient solution, adding compressed fluid until precipitation of active ingredient caused by compressed fluid antisolvent effect, removing the solvent and compressed fluid; drug delivery
08/28/2003US20030161938 Base layer selected from hyaluronic acid, poly-lysine and a peptide, and biocompatible layer selected from polysaccharides, lipids, proteins, heparin, heparan sulfate, hirudin and aprotinin
08/28/2003US20030161902 Dose of flavonoids extracted from pine bark extract decreases rate of senescence of mammal after onset of senescence; also increases mammal lifespan and increases neuromuscular performance after onset of senescence; antioxidants
08/28/2003US20030161900 Use of a dihydrochalcone-rich phenolic fraction in a cosmetic treatment
08/28/2003US20030161899 For prophylaxis of inhalation allergic reactions comprising mixture of saturated hydrocarbons having viscosity of greater than 6 mm2/s123n; treatment of atopic rhinitis in the form of "hayfever"
08/28/2003US20030161895 Comprising water, Xanthan gum, Magnesium aluminum silicate, Kaolin, Silicon dioxide, Sodium sulfacetamide, Sodium thiosulfate, Glyceryl stearate, PEG-100 Stearate, Quillaia saponaria extract, Benzyl alcohol, sulfur, high sorption base
08/28/2003US20030161893 PTPase inhibitors and methods of using the same
08/28/2003US20030161892 Cumin in powder or oil form is blood clotter in combination with unctuous host substance including petroleum jelly, coconut butter and antiseptics
08/28/2003US20030161890 Administering composition comprising water and/or fat-soluble cytosolic extract of pollen combined with Royal Jelly and vitamin E for treatment of disorders related to hormonal variations during fertile, peri- and post menopausal age
08/28/2003US20030161888 Pharmaceutical Composition
08/28/2003US20030161885 Agent having prolonged stomach retention time used to produce a longlasting saturation effect, and the use thereof
08/28/2003US20030161884 Formulation based on heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base
08/28/2003US20030161883 Composition consisting of an active ingredient and a therapeutically active delivery system, especially in the treatment of angiogenesis
08/28/2003US20030161882 Osmotic delivery system
08/28/2003US20030161880 Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
08/28/2003US20030161879 Tablets quickly disintegrating in mouth
08/28/2003US20030161878 Pharmaceutical pills having storage stability formed by mixing alendronic acid and/or sodium salts, binders, lubricants and diluents, used for prophylaxis of bone disorders such as osteoporosis
08/28/2003US20030161877 Administering mixtures of 5-(2-pyrazinyl)-4-methyl-1,2-dithiol -3-thione (oltipraz) and dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylene dioxybiphenyl-2, 2'-dicarboxylate (DDB) for prophylaxis of liver disorders; nontoxic
08/28/2003US20030161875 Fast dissolving tablets of cyclooxygenase-2 enzyme inhibitors
08/28/2003US20030161874 Sustained release dosages containing bupropion hydrochloride carriers and optionally binders or coatings; antidepressants
08/28/2003US20030161871 Intensifying water solubility of vitamin B12 using solubilizers such as complexing agents, liposomes, oils, surfactants, cosolvents or (micro)emulsions; multicompartment drug delivery kits
08/28/2003US20030161870 Dual enhancer composition for topical and transdermal drug delivery
08/28/2003US20030161868 Transdermal drug delivery systems having coverings comprising woven polyester layers, acrylic adhesives containing mixtures of ketoprofen and diclofenac
08/28/2003US20030161867 Skin-permeable selective cyclooxygenase-2 inhibitor composition
08/28/2003US20030161866 Complex comprising colloid particles having ion exchange capacity, joined to hydrophobic ligands and drugs such as N,N-diethyl-M-toluamide, to prevent or reduce skin absorption
08/28/2003US20030161865 Substrates such as tampons containing drugs such as thiolactomycin or thiomalonate, used to suppress production of toxic shock syndrome toxin (TSST) by grampositive bacteria
08/28/2003US20030161864 Lipid and food compositions containing docosahexaenoic acid and docosapentaenoic acid
08/28/2003US20030161863 Administering mixtures of nutrients for prophylaxis of muscular, metabolic or respiratory disorders, injuries, inflammation and/or to relieve stress
08/28/2003US20030161862 Bacterial growth regulators or inhibitors with the use of 1,5-d-anhydrofructose
08/28/2003US20030161860 Novel substituted aryl alkenoic acid heterocyclic amides
08/28/2003US20030161858 Mixtures of cement powders, vitamins, hormones, antibiotics, antitumor agents, somatotropins, calcium phosphates or proteins dissolved, dispersed or emulsified in oils; bone disorders
08/28/2003US20030161847 Oil bodies in cosmetics and/or pharmaceuticals obtained by ring opening of olefin-epoxides by an alcohol; nonsticky, very rapidly occurring and longer-lasting feel of skin smoothness; good solution behavior for lipophilic additives
08/28/2003US20030161846 Oral administration of an emulsion pre-concentrate of a nitrogen oxide-releasing NSAID, a surfactant, and an oil or fat; forms an oil-in-water emulsion with gastrointestinal fluids; side- effect reduction; bioavailability
08/28/2003US20030161834 Adjuvant compositions comprising a saponin and and an immunostimulatory oligonucleotide containing unmethylated CpG (a cytosine guanosine dinucleotide DNA motif); synergistic induction of antigen; anticarcinogenic agents
08/28/2003US20030161832 Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate specific membrane antigen
08/28/2003US20030161823 Therapeutic and cosmetic uses of heparanases
08/28/2003US20030161821 Pharmaceutical composition
08/28/2003US20030161820 Prevent infections; antiulcer agents
08/28/2003US20030161816 Systems and methods for treating patients with processed lipoaspirate cells
08/28/2003US20030161812 Using vitamin b12 compound; controlling gene expression
08/28/2003US20030161811 Method for treating cervical cancer
08/28/2003US20030161810 Methods and materials for treating inflammatory diseases
08/28/2003US20030161799 Practical and humane method for armpit odor care
08/28/2003US20030161797 Method of reducing and treating UVB-induced immunosuppression
08/28/2003US20030161793 UV-photostabilized sunscreen compositions comprising dibenzoylmethane/benzophenone compounds
08/28/2003US20030161791 Water-soluble polymer conjugates of retinoic acid
08/28/2003US20030161788 System for monitoring bacterial tumor treatment
08/28/2003US20030159953 Carbohydrate medical solution and sulphite stabilisator in a multiple compartment container and use thereof
08/28/2003US20030159702 Formulation and use manufacture thereof
08/28/2003US20030159341 Liquid mixture consisting of diesel gas oils and oxygenated compounds
08/28/2003DE29924428U1 New topical composition for treating herpes family viruses, reduces treatment-related erythema but maintains high activity
08/28/2003CA2512020A1 Compositions and methods for delivery of skin cosmeceuticals
08/28/2003CA2489498A1 An antimicrobial agent
08/28/2003CA2486381A1 Lipase inhibiting composition
08/28/2003CA2477321A1 Absorption enhancing agent
08/28/2003CA2476956A1 Strategy for retroviral immunotherapy
08/28/2003CA2476936A1 Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor
08/28/2003CA2476935A1 Drug delivery system for subconjunctival administration of fine particles
08/28/2003CA2476854A1 Surrogate antibodies and methods of preparation and use thereof
08/28/2003CA2476837A1 Sodium channel blockers
08/28/2003CA2476834A1 Natural cyclodextrin complexes of cannabinoids
08/28/2003CA2476832A1 Use of an inhibitor or antagonist against tissue factor
08/28/2003CA2476822A1 Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents
08/28/2003CA2476771A1 A preparation and method for weight reduction
08/28/2003CA2476764A1 Compositions and methods for surrogate antibody modulation of an immune response and transport
08/28/2003CA2476761A1 Therapeutic methods employing pai-1 inhibitors and transgenic non-human animal for screening candidate pai-1 inhibitors
08/28/2003CA2476681A1 Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease
08/28/2003CA2476665A1 Tricyclic pyrazole derivatives for the treatment of inflammation
08/28/2003CA2476624A1 Azabicyclic compounds for the treatment of disease
08/28/2003CA2476621A1 Inhalation powder containing the cgrp antagonist bibn4096 and process for the preparation thereof
08/28/2003CA2476451A1 Hyaluronic acid mediated adenoviral transduction
1 ... 5361 5362 5363 5364 5365 5366 5367 5368 5369 5370 5371 5372 5373 5374 5375 5376 5377 5378 5379 5380 5381 ... 7860